Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05634499 · ClinicalTrials.gov registry record · Phase 2
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 12
- Study locations
NCT05634499: Active Phase 2 study of Endometrial Cancer, sponsored by Hoffmann-La Roche.
NCT05634499 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 30 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05634499, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
Primary Outcome
The percentage of participants who have regression is defined as participants who have a decrease in the proportion of cancer in their endometrial biopsy or the proportion of cancer is not increased, but there is an increase in non-cancer/non-atypical hyperplasia at the 6-month assessment compared with baseline.
Conditions Studied
Interventions
- DRUG Giredestrant
Study Locations (12)
Quebec
- Jewish General Hospital - Montreal
- McGill University Health Centre - Glen Site - Montreal
Other
- Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice - Gliwice
- Swietokrzyskie Centrum Onkologii - Kielce
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Florida
- Mount Sinai Medical Center - Miami Beach
Minnesota
- Minnesota Oncology Minneapolis - Minneapolis
New Jersey
- Englewood Health/Hematology Oncology Practice of Englewood (HOPE) - Englewood
Pennsylvania
- Western Pennsylvania Hospital - Pittsburgh
Texas
- Texas Oncology, P.A. - Fort Worth - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT05634499 still lists
NCT05634499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Giredestrant is the first listed.
NCT05634499 lists 12 locations in 10 states (Quebec, Other, Arkansas).
Frequently Asked Questions
What is clinical trial NCT05634499 about?
NCT05634499 is a clinical study titled "A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer". This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
What is the current status of trial NCT05634499?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-06-27. Estimated completion is 2026-06-30.
What conditions does trial NCT05634499 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT05634499?
The interventions under investigation include: Giredestrant (DRUG).
Who is sponsoring clinical trial NCT05634499?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05634499 being conducted?
This trial has 12 study locations across Arkansas, Florida, Minnesota, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05634499's enrollment target sits among peer trials
30 147th of 181 higher than 28 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI